Transplant News and Research

RSS
FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

New path involving "innocent spectators" to defeat systemic sclerosis

New path involving "innocent spectators" to defeat systemic sclerosis

New research evaluating substantial disease burden of PNH presented at European Hematology Association

New research evaluating substantial disease burden of PNH presented at European Hematology Association

Discarded livers have potential to be reengineered into usable replacement organs: Researchers

Discarded livers have potential to be reengineered into usable replacement organs: Researchers

Clinical data from investigational study of patients with multiple myeloma presented at ASCO

Clinical data from investigational study of patients with multiple myeloma presented at ASCO

Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL

Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL

Genzyme, Carl C. Icahn announce agreement to settle proxy contest

Genzyme, Carl C. Icahn announce agreement to settle proxy contest

Vital Therapies commences enrollment in ELAD SILVER trial for acute-on-chronic liver failure

Vital Therapies commences enrollment in ELAD SILVER trial for acute-on-chronic liver failure

UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study

UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study

Combined cardiac bypass and liver tumor surgery performed on 63-year-old Nigerian

Combined cardiac bypass and liver tumor surgery performed on 63-year-old Nigerian

Scientists combine two agents to treat patients with multiple myeloma

Scientists combine two agents to treat patients with multiple myeloma

Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL

Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Cytheris completes €12 million Series D financing

Cytheris completes €12 million Series D financing

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Positive data on retreatment with brentuximab vedotin in Hodgkin lymphoma, ALCL presented at ASCO

Positive data on retreatment with brentuximab vedotin in Hodgkin lymphoma, ALCL presented at ASCO

Montefiore-Einstein announces Abdominal Organ Transplant Symposium on June 10, 2010

Montefiore-Einstein announces Abdominal Organ Transplant Symposium on June 10, 2010

Two-stage procedure reduces bone loss in oral implants

Two-stage procedure reduces bone loss in oral implants

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.